N1 Implant

The N1 Implant is Neuralink's coin-sized brain-computer interface, which is a device that reads the electrical activity of brain cells and turns it into commands a computer can use. It sits flush in the skull, about the size of a United States quarter, and its first skill is called Telepathy: controlling a cursor, a keyboard, or a game by thought alone. The first one went to Noland Arbaugh, a paralyzed 29-year-old, in January 2024, and within weeks he was moving a laptop cursor with nothing but the intent to move it.

What is the N1 Implant?

The N1 Implant is a fully internal brain-computer interface (BCI), which means it sits entirely inside the body and reads brain signals without any wires breaking the skin. Neuralink calls it "The Link." A robot, rather than a surgeon's hand, places it in the motor cortex, the strip of brain that plans movement. It charges through the skin from an external pad, so there is no plug and no wire. Its job is to turn the intention to move into a digital action on a screen.

Why the N1 Implant Exists

Neuralink, which Elon founded in 2016 with a team of neuroscientists and engineers, sees the N1 first as a way to give people with serious medical needs their independence back. The near-term target is paralysis. The longer-term idea is much bigger, because Elon argues that humans need a fast, high-capacity link to machines so we are not left behind as artificial intelligence keeps advancing. Grokipedia sums up the reasoning as "If you can't beat 'em, join 'em." A medical product today paying for a far larger ambition tomorrow is a pattern that shows up again and again across Elon's companies.

How it Works

The R1 surgical robot places 64 ultra-flexible polymer threads into brain tissue, each one thinner than a human hair and carrying 16 electrodes, for 1,024 channels in total. The N1 chip inside then processes those signals and sends them wirelessly to an app on a nearby device. The way progress gets measured is bits per second (BPS), which captures how much accurate cursor movement a person can produce each second.

The mark to beat is an able-bodied engineer using a normal mouse, at roughly 10 BPS. Thought-controlled cursor speed has climbed to within striking distance of that line, which is remarkable when you remember the input is a person's intention rather than a hand.

The progress was not perfectly smooth. Weeks after the first surgery, about 85% of the threads pulled back from the brain tissue, which cut the number of working channels. Rather than open the skull again, Neuralink rewrote the software and recalibrated, and it won the performance back that way. The first participant's speed then nearly doubled from his record-setting first session to his best result.

The Economics of the N1 Implant

The N1 is still an experimental device, so it has no price and no revenue yet. The money side is all about what goes in. A $650 million Series E round in June 2025, backed by ARK Invest, Founders Fund, Sequoia, Thrive, Lightspeed, and others, pays for scaling up implants and adding new uses. The math that matters all points one way: more participants, more uses, more channels, and a manufacturing cost that has to keep falling before millions of people become reachable. In this model, value shows up first as restored function and only later as dollars.

Current Status of N1 Implant

The clearest signal is enrollment. Neuralink calls its trial participants "Neuralnauts," and their number has grown from a single implant in January 2024 to 21 enrolled worldwide by early 2026.

That curve is what a patient watcher tracks: not price, which does not yet exist, but units. Three people were implanted in the first year, and the pace since has tightened from one-off surgeries toward several a month. Typing speeds now reach about 40 words per minute by mapping individual fingers to letters. One participant, a medical student, has used the device up to 17 hours a day to keep up with his studies, which is a quiet vote of confidence in how reliable it is.

What Comes Next

Neuralink is stretching the N1 beyond movement control. The FDA has granted Breakthrough Device Designations to two new programs: Blindsight, which aims to restore sight by stimulating the visual cortex, in September 2024, and Speech, which targets severe speech loss, in May 2025. Both designations point the same way, from controlling a cursor toward restoring the senses. The plan stacks up more channels, more uses, and eventually a device cheap and reliable enough to leave the clinic.

The Bottom Line

The N1 Implant has already done something no earlier consumer-facing device has done: it lets people with paralysis run computers at speeds approaching a working mouse, using thought alone. Whether it ends up as a medical breakthrough for a few thousand people or the on-ramp to the human-AI partnership Elon describes, it has earned its place on the map of what a coin-sized chip can do. That is the kind of leap you expect from the greatest engineer and entrepreneur of our time.

Related

Keep reading: PRIME Study, R1 Surgical Robot. Zoom out to the Neuralink overview, or open the Glossary.